Grant of Interim Extension of the Term of U.S. Patent No. 8,858,612; Reducer®, 13278 [2022-04969]
Download as PDF
<![CDATA[
13278
Federal Register / Vol. 87, No. 46 / Wednesday, March 9, 2022 / Notices
Dated: March 4, 2022.
Tracey L. Thompson,
Acting Deputy Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2022–05002 Filed 3–8–22; 8:45 am]
BILLING CODE 3510–22–P
DEPARTMENT OF COMMERCE
Robert Bahr,
Deputy Commissioner for Patents, United
States Patent and Trademark Office.
Patent and Trademark Office
[Docket No. PTO–P–2022–0009]
[FR Doc. 2022–04969 Filed 3–8–22; 8:45 am]
Grant of Interim Extension of the Term
of U.S. Patent No. 8,858,612; Reducer®
BILLING CODE 3510–16–P
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
DEPARTMENT OF COMMERCE
AGENCY:
Patent and Trademark Office
VerDate Sep<11>2014
17:44 Mar 08, 2022
Jkt 256001
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 6,953,476.
FOR FURTHER INFORMATION CONTACT: Ali
Salimi, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–0909 or by email
to ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On February 22, 2022, Neovasc
Medical Ltd., the patent owner of
record, timely filed an application
under 35 U.S.C. 156(d)(5) for a third
interim extension of the term of U.S.
Patent No. 6,953,476. The patent claims
a catheter delivered implantable device,
Reducer®. The application for patent
term extension indicates that a
Premarket Approval Application (PMA)
P190035 was submitted to the Food and
Drug Administration (FDA) on
December 31, 2019. Review of the
patent term extension application
indicates that, except for permission to
market or use the product commercially,
the subject patent would be eligible for
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Robert Bahr,
Deputy Commissioner for Patents, United
States Patent and Trademark Office.
BILLING CODE 3510–16–P
Grant of Interim Extension of the Term
of U.S. Patent No. 6,953,476; Reducer®
SUMMARY:
an extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because the
regulatory review period will continue
beyond the extended expiration date of
the patent, March 27, 2022, interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
6,953,476 is granted for a period of one
year from the extended expiration date
of the ’476 patent.
[FR Doc. 2022–04970 Filed 3–8–22; 8:45 am]
[Docket No.: PTO–P–2022–0003]
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 8,858,612.
FOR FURTHER INFORMATION CONTACT: Ali
Salimi, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–0909 or by email
to ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On February 22, 2022, Neovasc
Medical Ltd., the patent owner of
record, timely filed an application
under 35 U.S.C. 156(d)(5) for a third
interim extension of the term of U.S.
Patent No. 8,858,612. The patent claims
methods of using a catheter delivered
implantable device known by the
tradename Reducer®. The application
for patent term extension indicates that
a Premarket Approval Application
(PMA) P190035 was submitted to the
Food and Drug Administration (FDA) on
December 31, 2019.
Review of the patent term extension
application indicates that, except for
permission to market or use the product
commercially, the subject patent would
be eligible for an extension of the patent
term under 35 U.S.C. 156, and that the
patent should be extended for one year
as required by 35 U.S.C. 156(d)(5)(B).
Because the regulatory review period
will continue beyond the extended
expiration date of the patent, March 27,
SUMMARY:
jspears on DSK121TN23PROD with NOTICES1
2022, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
8,858,612 is granted for a period of one
year from the extended expiration date
of the ’612 patent.
BUREAU OF CONSUMER FINANCIAL
PROTECTION
[Docket No. CFPB–2022–0017]
Agency Information Collection
Activities: Comment Request
Bureau of Consumer Financial
Protection.
ACTION: Notice and request for comment.
AGENCY:
In accordance with the
Paperwork Reduction Act of 1995
(PRA), the Consumer Financial
Protection Bureau (CFPB or Bureau)
requests the extension of the Office of
Management and Budget’s (OMB’s)
approval of the existing information
collection titled ‘‘Electronic Fund
Transfer Act (Regulation E)’’ approved
under OMB Control Number 3170–0014.
DATES: Written comments are
encouraged and must be received on or
before April 8, 2022 to be assured of
consideration.
SUMMARY:
Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. In general, all
comments received will become public
records, including any personal
information provided. Sensitive
personal information, such as account
numbers or Social Security numbers,
should not be included.
FOR FURTHER INFORMATION CONTACT:
Documentation prepared in support of
this information collection request is
available at www.regulations.gov.
Requests for additional information
ADDRESSES:
E:\FR\FM\09MRN1.SGM
09MRN1
]]>Agencies
[Federal Register Volume 87, Number 46 (Wednesday, March 9, 2022)]
[Notices]
[Page 13278]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04969]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2022-0009]
Grant of Interim Extension of the Term of U.S. Patent No.
8,858,612; Reducer[supreg]
AGENCY: United States Patent and Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting a one-year interim extension of the term of U.S. Patent
No. 8,858,612.
FOR FURTHER INFORMATION CONTACT: Ali Salimi, Senior Legal Advisor,
Office of Patent Legal Administration, by telephone at 571-272-0909 or
by email to [email protected].
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On February 22, 2022, Neovasc Medical Ltd., the patent owner of
record, timely filed an application under 35 U.S.C. 156(d)(5) for a
third interim extension of the term of U.S. Patent No. 8,858,612. The
patent claims methods of using a catheter delivered implantable device
known by the tradename Reducer[supreg]. The application for patent term
extension indicates that a Premarket Approval Application (PMA) P190035
was submitted to the Food and Drug Administration (FDA) on December 31,
2019.
Review of the patent term extension application indicates that,
except for permission to market or use the product commercially, the
subject patent would be eligible for an extension of the patent term
under 35 U.S.C. 156, and that the patent should be extended for one
year as required by 35 U.S.C. 156(d)(5)(B). Because the regulatory
review period will continue beyond the extended expiration date of the
patent, March 27, 2022, interim extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 8,858,612 is granted for a period of one year from the
extended expiration date of the '612 patent.
Robert Bahr,
Deputy Commissioner for Patents, United States Patent and Trademark
Office.
[FR Doc. 2022-04969 Filed 3-8-22; 8:45 am]
BILLING CODE 3510-16-P
